Canaccord Genuity analyst John Newman has maintained their bullish stance on ONCY stock, giving a Buy rating yesterday. John Newman has given ...

BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Discover why Inhibrx is a hidden gem in biotech, poised for major growth with innovative treatments. For more investment ...

A rather odd week in venture, as the biggest rounds were raised by greentech, business travel and charity startups. Of course ...

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...